Analysis published 10 Oct 2026
AI-generated · cited to primary sources · not investment advice
Moderna, Inc. (MRNA) Dec 2025 Filing Analysis
02 · Business Model
How durable is the business?
Biotechnology Market Structure
40/100
Europe contracted dramatically, with product sales falling from $573 million to $50 million and its share dropping from 18.4% to 2.8%. Management attributed the decline to completed advance-purchase agreements and lower demand, while also noting competitive exclusion in certain European markets. (1 contracting, 1 shifted)
“Europe $50 million in 2025 versus $573 million in 2024.”
Moderna, Inc. - Common Stock · Annual Report · Dec 2025 · p.118
See the full cited Business Model analysis of Moderna, Inc.
Keep Reading
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.